Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Bereum Secures FDA, Journal, Patents

Bereum Co., Ltd. (CEO Han Kwon-il), a company specializing in postbiotics, has fully kick-started its campaign to capture the global healthcare market, spearheaded by its kimchi-derived proprietary strain, ‘beLP1® (Lactiplantibacillus plantarum)’.Bereum recently completed the registration of ‘beLP1®

Bereum Co., Ltd., a company specializing in postbiotics, has achieved significant milestones in its global healthcare market campaign. At the core of their success is the proprietary strain 'beLP1®' derived from kimchi. The company has successfully registered 'beLP1®' as a New Dietary Ingredient (NDI) with the United States Food and Drug Administration (FDA), marking a crucial step in ensuring the safety and regulatory compliance of their ingredient.

This FDA approval not only guarantees the flawless safety of their product but also positions Bereum at the forefront of international standards.

The scientific backing for 'beLP1®' has been bolstered by a randomized, double-blind, placebo-controlled human study published in the prestigious 'Frontiers in Nutrition' journal. This study involved 140 overweight adults with a BMI of 25 to 35 kg/m² and demonstrated that consuming 'beLP1®' (over 30 billion cells) daily resulted in a significant decrease in gastrointestinal symptoms, particularly abdominal pain and indigestion, compared to a placebo group.

Additionally, the study showed notable improvements in perceived stress levels and quality of life related to digestion. These results, highlighting the gut microbiome's beneficial bacteria increase and harmful pathogens decrease, underline the powerful gut health benefits of Bereum's technology.

Building on their initial FDA NDI registration, Bereum has further solidified its technological prowess through the registration of core patents. These patents cover areas such as metabolic diseases and mental health, providing a strong legal monopoly for their differentiated postbiotics technology. Their ambition has been evident in securing these intellectual property protections, moving beyond the patent application stage to complete patent registrations for anti-stress compositions and obesity improvement compositions.

This comprehensive approach to regulatory approval, scientific validation, and IP protection sets a robust foundation for Bereum to enter the global market and expand its influence across North America and beyond.

Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at businesskorea.co.kr →

More in Health & Medicine

Discovery Lifts 2027 Medical Aid Fees 8.2% on Average

Discovery will raise contributions by 8.2% and Momentum by 7.9% from January 2027, both far above the regulator's 3.8% anchor.

  • Discovery Health Medical Scheme proposes 8.2% average fee increase in 2027
  • Momentum Medical Scheme plans 7.9% average fee increase in 2027
  • Increases exceed CMS regulatory anchor of 3.8% for 2027

More from Friday 2 October →